How to Get Enclomiphene Citrate in New Hampshire

What Enclomiphene Citrate Is and Why It Is Prescribed in New Hampshire

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen receptors and thereby increases pulsatile GnRH release, which in turn raises LH and FSH and stimulates endogenous testosterone production. Physicians in New Hampshire prescribe it off-label to men with secondary hypogonadism whose HPG axis remains intact but underactive. Unlike testosterone replacement therapy, enclomiphene preserves testicular volume and spermatogenesis, making it a preferred option for men who wish to maintain fertility while correcting low testosterone.

Kim et al. (BJU Int, 2016, N=124) found that enclomiphene citrate 12.5 mg and 25 mg daily raised mean morning testosterone from hypogonadal levels to within the normal reference range (300 to 1 to 050 ng/dL) after 12 weeks, while men on topical testosterone saw significant declines in LH and FSH 1. A separate Phase III study reported in the same trial series confirmed that 25 mg/day produced mean total testosterone of approximately 500 ng/dL at week 12 with LH and FSH remaining above baseline, preserving the pituitary-testicular axis throughout 1.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming a diagnosis with two morning testosterone measurements below 300 ng/dL before initiating any testosterone-raising therapy, and specifies that secondary hypogonadism (low or inappropriately normal LH/FSH with low testosterone) is the appropriate diagnostic context for agents that act at the hypothalamic-pituitary level 2. Enclomiphene fits squarely within that mechanism.

New Hampshire has no state-specific restrictions on prescribing SERMs for men, so the pathway to a prescription follows federal off-label prescribing rules and standard board-of-medicine informed-consent requirements.

Telehealth Prescribing of Enclomiphene Citrate in New Hampshire

New Hampshire law explicitly permits telehealth prescribing. Telemedicine is governed under RSA 329:1-d, which allows a licensed physician to establish a valid patient-physician relationship via synchronous audiovisual technology and then issue a prescription without an in-person visit, provided an appropriate medical evaluation occurs 3. Nurse practitioners holding full prescriptive authority under New Hampshire's nurse practice act (RSA 326-B) may also prescribe enclomiphene via telehealth without a physician co-signature, because New Hampshire is a full-practice-authority state for APRNs 4.

The practical consequence is that a New Hampshire man can complete the entire process without leaving home. He books a video visit, uploads or transmits his lab results, discusses symptoms, and receives a prescription electronically sent to a 503A compounding pharmacy that ships to his address.

Controlled substances require a DEA-registered in-person evaluation under the Ryan Haight Act, but enclomiphene is not a controlled substance. That distinction matters because it removes the single largest barrier that prevents fully remote prescribing of medications like testosterone or anabolic steroids 5.

Telehealth platforms serving New Hampshire patients must hold an active NH medical or APRN license. Patients should verify licensure through the New Hampshire Office of Professional Licensure and Certification (OPLC) before starting care.

Labs Required Before a New Hampshire Provider Can Prescribe Enclomiphene

No reputable NH provider will prescribe enclomiphene without a baseline hormone panel. The standard pre-treatment workup recommended by the American Urological Association (AUA) 2018 Evaluation and Management of Testosterone Deficiency guideline includes at minimum: two fasting morning total testosterone draws (collected between 7 and 10 a.m.), LH, FSH, prolactin, estradiol (E2), a complete blood count, and a comprehensive metabolic panel 6. Providers frequently add SHBG to calculate free testosterone when total testosterone sits near the 300 to 400 ng/dL borderline range 7.

Secondary hypogonadism specifically requires confirmation that LH and FSH are low or inappropriately normal in the setting of low testosterone. If LH and FSH are both elevated (primary hypogonadism, e.g., Klinefelter syndrome), enclomiphene will not work because the testes themselves are not responding to gonadotropins, so the HPG-stimulation mechanism has no downstream target 2.

A prolactin level is checked to rule out a prolactinoma, which can suppress LH/FSH and mimic secondary hypogonadism. A prolactin above 20 ng/mL in a man warrants MRI of the pituitary before starting any SERM 8.

Most NH telehealth platforms integrate with LabCorp or Quest Diagnostics locations statewide. Manchester, Nashua, Concord, and Portsmouth all have multiple draw sites. Patients in northern NH near Littleton or Berlin may need to drive 30 to 60 minutes to the nearest draw center, though some providers accept results from small regional hospital labs.

Typical turnaround for standard hormone panels at commercial labs is 24 to 72 hours. Once results are received and reviewed, a licensed clinician either approves the prescription or schedules a follow-up video visit to discuss findings.

How New Hampshire's 503A Compounding Pharmacies Dispense Enclomiphene

Enclomiphene citrate does not currently have an FDA-approved commercially manufactured product that is actively marketed in the United States for male secondary hypogonadism; the compound is therefore prepared by 503A compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act and New Hampshire Board of Pharmacy regulations 9. A 503A compounder compounds medications for individual patients based on a valid prescription from a licensed prescriber and may ship across state lines to NH patients as long as the pharmacy holds appropriate reciprocal or non-resident licensure recognized by NH 9.

Enclomiphene is typically compounded as an oral capsule or tablet in strengths of 12.5 mg or 25 mg. Some pharmacies offer a sublingual troche formulation. Capsules and tablets are the most studied delivery forms, matching the oral dosing studied in the Kim et al. BJU Int trial 1.

Cash-pay pricing for compounded enclomiphene in New Hampshire ranges from approximately $60 to $120 per month for a 25 mg daily supply depending on the pharmacy and formulation. NH Medicaid does not cover enclomiphene for secondary hypogonadism because the indication is off-label, and most commercial insurance plans apply the same logic, though pre-authorization requests occasionally succeed when the prescriber documents two testosterone values below 300 ng/dL and a clear secondary pattern on the LH/FSH panel 10.

Step-by-Step: Getting Your First Enclomiphene Prescription in New Hampshire

Step 1. Choose a licensed NH provider or telehealth platform. Confirm the prescriber holds a current New Hampshire medical, APRN, or PA license through OPLC. For telehealth, verify the platform uses synchronous video (not asynchronous questionnaire only) to comply with RSA 329:1-d and to ensure a valid prescribing relationship is formed 3.

Step 2. Order baseline labs. Your provider will send lab orders to LabCorp, Quest, or another NH-licensed draw facility. Draw fasting, in the morning. The full panel (total testosterone x2, LH, FSH, prolactin, E2, SHBG, CBC, CMP) typically costs $150 to $250 cash-pay if insurance does not cover the draw. Results arrive within 24 to 72 hours 6.

Step 3. Attend your telehealth consultation. Bring your lab printout or PDF to the video visit. The clinician will confirm a diagnosis of secondary hypogonadism, review your symptom history (fatigue, reduced libido, poor morning erections, mood changes), discuss risks including potential estrogen elevation and the rare risk of visual disturbance from SERM use, and document informed consent 2.

Step 4. Prescription sent to 503A pharmacy. The prescriber transmits the Rx electronically. Standard prescriptions include the specific compound strength (commonly 25 mg), dosage form (oral capsule), quantity (30 capsules for a 30-day supply), and refills. The pharmacy verifies the prescription, compounds the batch, performs quality-control testing, and ships via tracked courier.

Step 5. Receive and begin therapy. Most NH patients receive their shipment in 5 to 7 business days. Some pharmacies in New England offer 2-day shipping to NH addresses. Begin dosing on the morning of day one, ideally at the same time each day. Schedule a follow-up testosterone draw at 6 to 8 weeks to confirm response 1.

Step 6. Monitor and adjust. If total testosterone remains below 400 ng/dL at 8 weeks on 12.5 mg, the provider may titrate to 25 mg daily. If estradiol rises above 40 pg/mL with symptoms (nipple tenderness, water retention), a low-dose aromatase inhibitor may be added or the enclomiphene dose reduced 7.

Who Can Prescribe Enclomiphene Citrate in New Hampshire

New Hampshire grants prescriptive authority for legend drugs (non-controlled prescription medications) to:

MDs and DOs licensed by the NH Board of Medicine. These physicians may prescribe enclomiphene without restriction as an off-label use under standard informed-consent practice 11.

Advanced Practice Registered Nurses (APRNs/NPs) with full prescriptive authority under RSA 326-B:18. New Hampshire is a full-practice-authority state, meaning NPs do not require physician oversight or a collaborative practice agreement to prescribe enclomiphene. This is confirmed in the 2020 National Academy of Medicine report on APRN scope of practice 4.

Physician Assistants (PAs) licensed under RSA 328-D. PAs in NH may prescribe legend drugs under a supervising physician agreement. A PA working in a men's health or endocrinology practice may prescribe enclomiphene with physician co-signature or collaborative agreement as required by their practice setting 12.

Naturopathic physicians in New Hampshire hold prescriptive authority for certain medications under RSA 328-E but their authority does not extend to compounded SERMs in the same scope as MDs or APRNs. Patients seeking naturopathic care should confirm the ND's specific formulary authority with OPLC before assuming enclomiphene will be prescribed.

Monitoring Protocol During Enclomiphene Therapy in New Hampshire

Prescribers following evidence-based practice track a defined set of markers at regular intervals once therapy begins. The Endocrine Society 2018 guideline recommends testosterone monitoring at 3 months after starting any testosterone-raising therapy and then annually if the patient is stable 2. Most NH telehealth providers follow a tighter schedule for the first 6 months given the off-label status:

Weeks 6 to 8: Total testosterone, free testosterone (or SHBG), LH, FSH, estradiol. This visit confirms the HPG axis is responding appropriately. A well-responding patient will show testosterone in the 400 to 700 ng/dL range with LH and FSH at or above baseline 1.

Month 3: Repeat full panel plus CBC (to check hematocrit, since rising testosterone can increase erythropoiesis even with SERMs, though less dramatically than injectable TRT) 13.

Month 6 and annually thereafter: Full hormone panel, CBC, lipid panel. The Kim et al. trial found no clinically significant adverse changes in lipid profiles or hepatic enzymes over 12 weeks at 12.5 mg or 25 mg daily 1.

Visual symptoms are an infrequent but documented concern with SERMs. Clomiphene citrate, the racemic parent compound from which enclomiphene is derived, is associated with visual disturbances in approximately 1.5% of users in studies of women, and the same mechanism applies to the trans-isomer 14. Patients should report blurred vision or light sensitivity to their provider immediately, as these are grounds for discontinuation.

Insurance, Prior Authorization, and Cash-Pay Options in New Hampshire

New Hampshire Medicaid (NH Healthy Families, Wellsense) does not cover enclomiphene for secondary hypogonadism because it is prescribed off-label. Commercial plans vary widely. Some Blue Cross Blue Shield of NH, Harvard Pilgrim, and Tufts Health Plan policies will cover compounded medications with a prior authorization request, but approval rates are low for off-label indications 10.

A prior authorization for commercial insurance in NH typically requires:

1. Two documented testosterone values below 300 ng/dL, drawn on separate mornings 6.
2. Documented LH/FSH pattern consistent with secondary (not primary) hypogonadism.
3. A letter of medical necessity from the prescriber citing peer-reviewed evidence, including the Kim et al. BJU Int 2016 trial 1.
4. Confirmation that the patient has trialed or is contraindicated for an FDA-approved testosterone product.

Cash-pay remains the most predictable route for NH patients. A 30-day supply of compounded enclomiphene 25 mg from a licensed 503A pharmacy runs approximately $80 to $120, with telehealth consultation fees typically $75 to $150 for the initial visit. Follow-up labs at LabCorp or Quest without insurance typically total $100 to $200 per draw.

Some NH patients use health sharing ministries or HSA/FSA accounts to offset costs. Prescription compounded medications prepared by a licensed 503A pharmacy are generally HSA/FSA-eligible under IRS Publication 502 15.

Transferring an Existing Enclomiphene Prescription to New Hampshire

Patients relocating to New Hampshire with an active enclomiphene prescription from another state face a straightforward process, provided the prescribing physician holds or obtains NH licensure or the patient establishes care with a new NH provider.

A 503A compounding pharmacy cannot continue filling a prescription issued by an out-of-state prescriber who is not licensed in New Hampshire. The prescriber must either obtain an NH license (common for large national telehealth platforms that maintain multi-state licensure) or the patient must transfer care 16.

To transfer, the new NH provider will typically want records of prior diagnoses (testosterone values, LH/FSH pattern), current dose, duration of therapy, and any monitoring labs from the prior 3 to 6 months. With those records, an NH telehealth clinician can often establish care and issue a new prescription within a single video visit, bypassing the need for a full repeat lab panel if recent results (within 3 months) are available 2.

The 503A pharmacy serving the patient will need the new NH prescription before shipping. Most pharmacies will hold a brief shipment gap of 3 to 7 days during the transfer period; ordering the new prescription before the existing supply runs out prevents a treatment gap 9.

Risks, Contraindications, and What New Hampshire Clinicians Screen For

Enclomiphene is generally well tolerated at doses of 12.5 to 25 mg daily. The Kim et al. trial reported that adverse events were mild, with headache (4.8%), nausea (3.2%), and mood changes (2.4%) among the most common at 25 mg/day 1. Gynecomastia is theoretically possible if estradiol rises disproportionately, though SERMs actually block estrogen receptors in breast tissue and may be protective against gynecomastia in the short term compared with exogenous testosterone 17.

Absolute contraindications screened at the NH intake visit include:

Elevated LH and FSH indicating primary (testicular) hypogonadism. Enclomiphene has no mechanism to act on non-responsive testes 2.

Prolactinoma or other pituitary mass. A prolactin above 20 ng/mL triggers MRI before any SERM prescription 8.

Active liver disease. SERMs are hepatically metabolized and carry a theoretical risk of cholestatic effects at higher doses, though the 12.5 to 25 mg range used in men is far below the doses used historically in female fertility treatment 18.

Prior thromboembolic events or known thrombophilia. Estrogen-modulating agents carry a small pro-thrombotic potential in susceptible individuals. Patients with a history of DVT or PE should discuss risk-benefit with a hematology-aware provider before starting 19.

History of retinal disease or unexplained visual changes. Given the SERM-class risk of visual disturbance, a baseline ophthalmologic review may be warranted in patients with prior retinal pathology 14.

The AUA 2018 guideline states: "Clomiphene citrate and its active isomers are reasonable options in men with secondary hypogonadism who wish to preserve fertility, provided that primary hypogonadism has been excluded by gonadotropin measurement." 6 NH providers are expected to document this exclusion before prescribing.